- Home
- PFL vs MREO Comparison
PFL vs MREO Comparison
Compare PFL & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PFL | MREO |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 374.5M | 324.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PFL | MREO |
|---|---|---|
| Price | $8.38 | $2.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | 113.7K | ★ 2.4M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 11.53% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $131.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.98 | $1.47 |
| 52 Week High | $8.62 | $3.88 |
Technical Indicators
Market Signals| Indicator | PFL | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 45.08 | 50.12 |
| Support Level | $8.37 | $1.89 |
| Resistance Level | $8.42 | $2.37 |
| Average True Range (ATR) | 0.04 | 0.17 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 15.79 | 40.48 |
Price Performance
Historical ComparisonAbout PFL PIMCO Income Strategy Fund Shares of Beneficial Interest
PIMCO Income Strategy Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek high current income, consistent with the preservation of capital. It seeks to achieve its objectives by investing in a diversified portfolio of floating and fixed-rate debt instruments.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).